secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0001193125-24-264714
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio Phase 1 INB-200 data: 50% of multi-dose patients alive beyond expected median OS
--------------------------------------------------------------------------------

- 50% of multi-dose patients (n=10) alive beyond expected median OS from Stupp regimen; none in single-dose group (n=3).
- Biopsy confirmed gamma-delta T cell persistence in brain tumor microenvironment in two patients post-treatment.
- Median PFS in repeat-dose patients increased 79% vs. 6.9 months for Stupp regimen.
- No treatment-related serious adverse events, cytokine release syndrome, or neurotoxicity reported.
- One IDH-mutant glioma patient remains alive and progression-free at 40.5 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524264714/0001193125-24-264714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312524264714/d844601d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-264714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer